NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-9.24%)
USD 0.49
(-9.24%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 14.72 Million USD | 2.24% |
| 2022 | 14.4 Million USD | 71.05% |
| 2021 | 8.42 Million USD | -15.23% |
| 2020 | 9.93 Million USD | 50.54% |
| 2019 | 6.59 Million USD | -47.24% |
| 2018 | 12.5 Million USD | -31.39% |
| 2017 | 18.23 Million USD | 53.23% |
| 2016 | 11.89 Million USD | 171.56% |
| 2015 | 4.38 Million USD | 315.65% |
| 2014 | 1.05 Million USD | -69.69% |
| 2013 | 3.47 Million USD | -49.95% |
| 2012 | 6.94 Million USD | -36.95% |
| 2011 | 11.01 Million USD | 12.97% |
| 2010 | 9.75 Million USD | -37.81% |
| 2009 | 15.68 Million USD | 133.32% |
| 2008 | 6.72 Million USD | 13.68% |
| 2007 | 5.91 Million USD | 285.71% |
| 2006 | 1.53 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.63 Million USD | -29.41% |
| 2024 Q2 | 2.4 Million USD | -8.78% |
| 2023 Q1 | 3.12 Million USD | -14.25% |
| 2023 FY | 14.72 Million USD | 2.24% |
| 2023 Q2 | 4.61 Million USD | 47.57% |
| 2023 Q3 | 3.25 Million USD | -29.39% |
| 2023 Q4 | 3.72 Million USD | 14.5% |
| 2022 Q4 | 3.64 Million USD | -4.78% |
| 2022 Q1 | 2.62 Million USD | -0.45% |
| 2022 FY | 14.4 Million USD | 71.05% |
| 2022 Q2 | 3.04 Million USD | 15.82% |
| 2022 Q3 | 3.82 Million USD | 25.65% |
| 2021 Q4 | 2.64 Million USD | 43.53% |
| 2021 FY | 8.42 Million USD | -15.23% |
| 2021 Q1 | 1.8 Million USD | -4.29% |
| 2021 Q2 | 2.13 Million USD | 18.04% |
| 2021 Q3 | 1.84 Million USD | -13.74% |
| 2020 Q4 | 1.88 Million USD | -13.0% |
| 2020 Q1 | 1.89 Million USD | 11.03% |
| 2020 Q2 | 3.98 Million USD | 110.57% |
| 2020 FY | 9.93 Million USD | 50.54% |
| 2020 Q3 | 2.17 Million USD | -45.53% |
| 2019 Q2 | 1.78 Million USD | 19.99% |
| 2019 Q4 | 1.7 Million USD | 5.51% |
| 2019 FY | 6.59 Million USD | -47.24% |
| 2019 Q1 | 1.49 Million USD | -58.87% |
| 2019 Q3 | 1.61 Million USD | -9.73% |
| 2018 Q2 | 2.79 Million USD | -5.19% |
| 2018 FY | 12.5 Million USD | -31.39% |
| 2018 Q3 | 3.14 Million USD | 12.46% |
| 2018 Q4 | 3.62 Million USD | 15.37% |
| 2018 Q1 | 2.94 Million USD | -53.34% |
| 2017 Q3 | 4.09 Million USD | -0.75% |
| 2017 Q2 | 4.12 Million USD | 11.38% |
| 2017 Q1 | 3.7 Million USD | -9.22% |
| 2017 FY | 18.23 Million USD | 53.23% |
| 2017 Q4 | 6.31 Million USD | 54.39% |
| 2016 Q1 | 1.71 Million USD | 5.14% |
| 2016 Q4 | 4.07 Million USD | 18.59% |
| 2016 FY | 11.89 Million USD | 171.56% |
| 2016 Q3 | 3.43 Million USD | 29.1% |
| 2016 Q2 | 2.66 Million USD | 54.92% |
| 2015 Q2 | 1 Million USD | 87.36% |
| 2015 Q4 | 1.63 Million USD | 36.25% |
| 2015 Q3 | 1.2 Million USD | 19.05% |
| 2015 FY | 4.38 Million USD | 315.65% |
| 2015 Q1 | 538 Thousand USD | 9.57% |
| 2014 Q4 | 491 Thousand USD | 223.03% |
| 2014 Q1 | 288 Thousand USD | -43.53% |
| 2014 FY | 1.05 Million USD | -69.69% |
| 2014 Q2 | 123 Thousand USD | -57.29% |
| 2014 Q3 | 152 Thousand USD | 23.58% |
| 2013 Q4 | 510 Thousand USD | -53.59% |
| 2013 Q2 | 848 Thousand USD | -16.86% |
| 2013 Q3 | 1.09 Million USD | 29.6% |
| 2013 FY | 3.47 Million USD | -49.95% |
| 2013 Q1 | 1.02 Million USD | -8.36% |
| 2012 Q4 | 1.11 Million USD | -69.44% |
| 2012 FY | 6.94 Million USD | -36.95% |
| 2012 Q1 | 1.32 Million USD | 7.32% |
| 2012 Q2 | 871 Thousand USD | -34.02% |
| 2012 Q3 | 3.64 Million USD | 318.14% |
| 2011 Q4 | 1.23 Million USD | -55.63% |
| 2011 Q2 | 4.52 Million USD | 81.81% |
| 2011 Q1 | 2.49 Million USD | -17.98% |
| 2011 FY | 11.01 Million USD | 12.97% |
| 2011 Q3 | 2.77 Million USD | -38.77% |
| 2010 Q3 | 2.08 Million USD | -18.13% |
| 2010 Q4 | 3.03 Million USD | 45.54% |
| 2010 Q2 | 2.54 Million USD | 22.26% |
| 2010 Q1 | 2.08 Million USD | -72.18% |
| 2010 FY | 9.75 Million USD | -37.81% |
| 2009 Q3 | 3.22 Million USD | 36.78% |
| 2009 Q2 | 2.35 Million USD | -9.73% |
| 2009 Q1 | 2.61 Million USD | 18.9% |
| 2009 FY | 15.68 Million USD | 133.32% |
| 2009 Q4 | 7.49 Million USD | 132.38% |
| 2008 Q1 | 1.49 Million USD | -1.91% |
| 2008 Q4 | 2.19 Million USD | 37.94% |
| 2008 Q3 | 1.59 Million USD | 10.4% |
| 2008 FY | 6.72 Million USD | 13.68% |
| 2008 Q2 | 1.44 Million USD | -3.35% |
| 2007 Q2 | 1.46 Million USD | -1.21% |
| 2007 Q1 | 1.48 Million USD | 11.92% |
| 2007 Q3 | 1.44 Million USD | -1.43% |
| 2007 Q4 | 1.52 Million USD | 5.33% |
| 2007 FY | 5.91 Million USD | 285.71% |
| 2006 Q3 | 208 Thousand USD | 0.0% |
| 2006 FY | 1.53 Million USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | 1.32 Million USD | 537.02% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 202 Thousand USD | -7190.099% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 4.52 Million USD | -225.149% |
| Actinium Pharmaceuticals, Inc. | 81 Thousand USD | -18080.247% |
| Azitra, Inc. | 686 Thousand USD | -2046.647% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | -1881.965% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | - USD | -Infinity% |
| iBio, Inc. | 225 Thousand USD | -6444.889% |
| Lineage Cell Therapeutics, Inc. | 8.94 Million USD | -64.628% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 1.09 Million USD | -1243.613% |
| Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | -22330.391% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 37.65 Thousand USD | -39009.765% |
| BiomX Inc. | -357 Thousand USD | 4224.93% |
| BiomX Inc. | -357 Thousand USD | 4224.93% |
| Protalix BioTherapeutics, Inc. | 65.49 Million USD | 77.515% |
| Palatin Technologies, Inc. | 4.49 Million USD | -227.967% |
| Scorpius Holdings, Inc. | 6.99 Million USD | -110.527% |